|
1
|
Kalluri R and Weinberg R: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Thiery JP, Acloque H, Huang RYJ and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yang J and Weinberg RA:
Epithelial-mesenchymal transition: At the crossroads of development
and tumor metastasis. Dev Cell. 14:818–829. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ye X and Weinberg RA:
Epithelial-mesenchymal plasticity: A central regulator of cancer
progression. Trends Cell Biol. 25:675–686. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kaufhold S and Bonavida B: Central role of
Snail1 in the regulation of EMT and resistance in cancer: A target
for therapeutic intervention. J Exp Clin Cancer Res. 33:622014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Grasset EM, Dunworth M, Sharma G, Loth M,
Tandurella J, Cimino-Mathews A, Gentz M, Bracht S, Haynes M, Fertig
EJ and Ewald AJ: Triple-negative breast cancer metastasis involves
complex epithelial-mesenchymal transition dynamics and requires
vimentin. Sci Transl Med. 14:eabn75712022. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tsoukalas N, Aravantinou-Fatorou E, Tolia
M, Giaginis C, Galanopoulos M, Kiakou M, Kostakis ID, Dana E,
Vamvakaris I, Korogiannos A, et al: Epithelial-mesenchymal
transition in non small-cell lung cancer. Anticancer Res.
37:1773–1778. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Palamaris K, Felekouras E and Sakellariou
S: Epithelial to mesenchymal transition: Key regulator of
pancreatic ductal adenocarcinoma progression and chemoresistance.
Cancers (Basel). 13:55322021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sessa C, Schneider DT, Planchamp F, Baust
K, Braicu EI, Concin N, Godzinski J, McCluggage WG, Orbach D,
Pautier P, et al: ESGO-SIOPE guidelines for the management of
adolescents and young adults with non-epithelial ovarian cancers.
Lancet Oncol. 21:e360–e368. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ghazarian AA, Kelly SP, Altekruse SF,
Rosenberg PS and McGlynn KA: Future of testicular germ cell tumor
incidence in the United States: Forecast through 2026. Cancer.
123:2320–2328. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pierce JL, Frazier AL and Amatruda JF:
Pediatric germ cell tumors: A developmental perspective. Adv Urol.
2018:90593822018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Culine S, Kramar A, Théodore C, Geoffrois
L, Chevreau C, Biron P, Nguyen BB, Héron JF, Kerbrat P, Caty A, et
al: Randomized trial comparing bleomycin/etoposide/cisplatin with
alternating cisplatin/cyclophosphamide/doxorubicin and
vinblastine/bleomycin regimens of chemotherapy for patients with
intermediate- and poor-risk metastatic nonseminomatous germ cell
tumors: Genito-Urinary Group Of The French Federation Of Cancer
Centers Trial T93MP. J Clin Oncol. 26:421–427. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pinto MT, Cárcano FM, Vieira AGS, Cabral
ERM and Lopes LF: Molecular biology of pediatric and adult male
germ cell tumors. Cancers (Basel). 13:23492021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
de Vries G, Rosas-Plaza X, van Vugt MATM,
Gietema JA and de Jong S: Testicular cancer: Determinants of
cisplatin sensitivity and novel therapeutic opportunities. Cancer
Treat Rev. 88:1020542020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Vega S, Morales AV, Ocaña OH, Valdés F,
Fabregat I and Nieto MA: Snail blocks the cell cycle and confers
resistance to cell death. Genes Dev. 18:1131–1143. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Saxena M, Stephens MA, Pathak H and
Rangarajan A: Transcription factors that mediate
epithelial-mesenchymal transition lead to multidrug resistance by
upregulating ABC transporters. Cell Death Dis. 2:e1792011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wu K and Bonavida B: The activated
NF-κB-Snail-RKIP circuitry in cancer regulates both the metastatic
cascade and resistance to apoptosis by cytotoxic drugs. Crit Rev
Immunol. 29:241–254. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lee HH, Lee SH, Song KY, Na SJ, O JH, Park
JM, Jung ES, Choi MG and Park CH: Evaluation of Slug expression is
useful for predicting lymph node metastasis and survival in
patients with gastric cancer. BMC Cancer. 17:6702017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gu A, Jie Y, Yao Q, Zhang Y and Mingyan E:
Slug is associated with tumor metastasis and angiogenesis in
ovarian cancer. Reprod Sci. 24:291–299. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bhat-Nakshatri P, Appaiah H, Ballas C,
Pick-Franke P, Goulet R Jr, Badve S, Srour EF and Nakshatri H:
SLUG/SNAI2 and tumor necrosis factor generate breast cells with
CD44+/CD24-phenotype. BMC Cancer. 10:4112010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shen H, Shih J, Hollern DP, Wang L, Bowlby
R, Tickoo SK, Thorsson V, Mungall AJ, Newton Y, Hegde AM, et al:
Integrated molecular characterization of testicular germ cell
tumors. Cell Rep. 23:3392–3406. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gu Z, Eils R and Schlesner M: Complex
heatmaps reveal patterns and correlations in multidimensional
genomic data. Bioinformatics. 32:2847–2849. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lengert AVH, Pereira LDNB, Cabral ERM,
Gomes INF, Jesus LM, Gonçalves MFS, Rocha AOD, Tassinari TA, Silva
LSD, Laus AC, et al: Potential new therapeutic approaches for
cisplatin-resistant testicular germ cell tumors. Front Biosci
(Landmark Ed). 27:2452022. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Silva-Oliveira RJ, Silva VAO, Martinho O,
Cruvinel-Carloni A, Melendez ME, Rosa MN, de Paula FE, de Souza
Viana L, Carvalho AL and Reis RM: Cytotoxicity of allitinib, an
irreversible anti-EGFR agent, in a large panel of human
cancer-derived cell lines: KRAS mutation status as a predictive
biomarker. Cell Oncol (Dordr). 39:253–263. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pfaffl MW: A new mathematical model for
relative quantification in real-time RT-PCR. Nucleic Acids Res.
29:e452001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Teixeira SA, Luzzi MC, Martin ACBM, Duarte
TT, Leal MO, Teixeira GR, Reis MT, Junior CRA, Santos K, Melendez
ME, et al: The barretos cancer hospital animal facility:
Implementation and results of a dedicated platform for preclinical
oncology models. Vet Sci. 9:6362022. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mikami S, Katsube KI, Oya M, Ishida M,
Kosaka T, Mizuno R, Mukai M and Okada Y: Expression of Snail and
Slug in renal cell carcinoma: E-cadherin repressor Snail is
associated with cancer invasion and prognosis. Lab Invest.
91:1443–1458. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gerwing M, Jacobsen C, Dyshlovoy S,
Hauschild J, Rohlfing T, Oing C, Venz S, Oldenburg J, Oechsle K,
Bokemeyer C, et al: Cabazitaxel overcomes cisplatin resistance in
germ cell tumour cells. J Cancer Res Clin Oncol. 142:1979–1994.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang J, Wei Q, Wang X, Tang S, Liu H,
Zhang F, Mohammed MK, Huang J, Guo D, Lu M, et al: Transition to
resistance: An unexpected role of the EMT in cancer
chemoresistance. Genes Dis. 3:3–6. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Smith B and Bhowmick N: Role of EMT in
metastasis and therapy resistance. J Clin Med. 5:172016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tang LH, Gonen M, Hedvat C, Modlin IM and
Klimstra DS: Objective quantification of the Ki67 proliferative
index in neuroendocrine tumors of the gastroenteropancreatic
system: A comparison of digital image analysis with manual methods.
Am J Surg Pathol. 36:1761–1770. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Klimowicz AC, Bose P, Petrillo SK,
Magliocco AM, Dort JC and Brockton NT: The prognostic impact of a
combined carbonic anhydrase IX and Ki67 signature in oral squamous
cell carcinoma. Br J Cancer. 109:1859–1866. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fukawa T and Kanayama H: Current knowledge
of risk factors for testicular germ cell tumors. Int J Urol.
25:337–344. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Rocha CRR, Silva MM, Quinet A, Cabral-Neto
JB and Menck CFM: DNA repair pathways and cisplatin resistance: An
intimate relationship. Clinics (Sao Paulo). 73 (Suppl 1):e478s2018.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Brasseur K, Gévry N and Asselin E:
Chemoresistance and targeted therapies in ovarian and endometrial
cancers. Oncotarget. 8:4008–4042. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Antony J, Thiery JP and Huang RYJ:
Epithelial-to-mesenchymal transition: Lessons from development,
insights into cancer and the potential of EMT-subtype based
therapeutic intervention. Phys Biol. 16:0410042019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wakileh GA, Bierholz P, Kotthoff M,
Skowron MA, Bremmer F, Stephan A, Anbuhl SM, Heukers R, Smit MJ,
Ströbel P and Nettersheim D: Molecular characterization of the
CXCR4/CXCR7 axis in germ cell tumors and its targetability using
nanobody-drug-conjugates. Exp Hematol Oncol. 12:962023. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bremmer F, Schallenberg S, Jarry H, Küffer
S, Kaulfuss S, Burfeind P, Strauß A, Thelen P, Radzun HJ, Ströbel
P, et al: Role of N-cadherin in proliferation, migration, and
invasion of germ cell tumours. Oncotarget. 6:33426–33437. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Classen J, Souchon R, Hehr T and Bamberg
M: Treatment of early stage testicular seminoma. J Cancer Res Clin
Oncol. 127:475–481. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
De Las Rivas J, Brozovic A, Izraely S,
Casas-Pais A, Witz IP and Figueroa A: Cancer drug resistance
induced by EMT: Novel therapeutic strategies. Arch Toxicol.
95:2279–2297. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lu W and Kang Y: Epithelial-mesenchymal
plasticity in cancer progression and metastasis. Dev Cell.
49:361–374. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Singh A and Settleman J: EMT, Cancer stem
cells and drug resistance: An emerging axis of evil in the war on
cancer. Oncogene. 29:4741–4751. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Singh D and Siddique HR:
Epithelial-to-mesenchymal transition in cancer progression:
Unraveling the immunosuppressive module driving therapy resistance.
Cancer Metastasis Rev. 43:155–173. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Solheim O, Førsund M, Tropé CG, Kraggerud
SM, Nesland JM and Davidson B: Epithelial-mesenchymal transition
markers in malignant ovarian germ cell tumors. APMIS. 125:781–786.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Schinke H, Pan M, Akyol M, Zhou J, Shi E,
Kranz G, Libl D, Quadt T, Simon F, Canis M, et al: SLUG-related
partial epithelial-to-mesenchymal transition is a transcriptomic
prognosticator of head and neck cancer survival. Mol Oncol.
16:347–367. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kim H, Lee SB, Myung JK, Park JH, Park E,
Il Kim D, Lee C, Kim Y, Park CM, Kim MB, et al: SLUG is a key
regulator of Epithelial-Mesenchymal transition in pleomorphic
adenoma. Lab Invest. 102:631–640. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Noguchi S, Hirano K, Tanimoto N, Shimada T
and Akiyoshi H: SLUG is upregulated and induces epithelial
mesenchymal transition in canine oral squamous cell carcinoma. Vet
Comp Oncol. 20:134–141. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Önder E, Çil N, Seçme M and Mete GA:
Effect of alpha lipoic acid on epithelial mesenchymal transition in
SKOV-3 cells. Gene. 892:1478802024. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Alves CC, Carneiro F, Hoefler H and Becker
KF: Role of the epithelial-mesenchymal transition regulator Slug in
primary human cancers. Front Biosci (Landmark Ed). 14:3035–3050.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Shih JY and Yang PC: The EMT regulator
slug and lung carcinogenesis. Carcinogenesis. 32:1299–1304. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Shih JY, Tsai MF, Chang TH, Chang YL, Yuan
A, Yu CJ, Lin SB, Liou GY, Lee ML, Chen JJ, et al: Transcription
repressor slug promotes carcinoma invasion and predicts outcome of
patients with lung adenocarcinoma. Clin Cancer Res. 11:8070–8078.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Martin TA, Goyal A, Watkins G and Jiang
WG: Expression of the transcription factors snail, slug, and twist
and their clinical significance in human breast cancer. Ann Surg
Oncol. 12:488–496. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Zivotic M, Kovacevic S, Nikolic G,
Mioljevic A, Filipovic I, Djordjevic M, Jovicic V, Topalovic N,
Ilic K, Radojevic Skodric S, et al: SLUG and SNAIL as potential
immunohistochemical biomarkers for renal cancer staging and
survival. Int J Mol Sci. 24:122452023. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Haslehurst AM, Koti M, Dharsee M, Nuin P,
Evans K, Geraci J, Childs T, Chen J, Li J, Weberpals J, et al: EMT
transcription factors snail and slug directly contribute to
cisplatin resistance in ovarian cancer. BMC Cancer. 12:912012.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Liang F, Ren C, Wang J, Wang S, Yang L,
Han X, Chen Y, Tong G and Yang G: The crosstalk between STAT3 and
p53/RAS signaling controls cancer cell metastasis and cisplatin
resistance via the Slug/MAPK/PI3K/AKT-mediated regulation of EMT
and autophagy. Oncogenesis. 8:592019. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Oh SJ, Ahn EJ, Kim O, Kim D, Jung TY, Jung
S, Lee JH, Kim KK, Kim H, Kim EH, et al: The role played by SLUG,
an Epithelial-Mesenchymal transition factor, in invasion and
therapeutic resistance of malignant glioma. Cell Mol Neurobiol.
39:769–782. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Shen CJ, Kuo YL, Chen CC, Chen MJ and
Cheng YM: MMP1 expression is activated by Slug and enhances
multi-drug resistance (MDR) in breast cancer. PLoS One.
12:e01744872017. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Chang L, Hu Y, Fu Y, Zhou T, You J, Du J,
Zheng L, Cao J, Ying M, Dai X, et al: Targeting slug-mediated
non-canonical activation of c-Met to overcome chemo-resistance in
metastatic ovarian cancer cells. Acta Pharm Sin B. 9:484–495. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Mancini M, Petta S, Iacobucci I,
Salvestrini V, Barbieri E and Santucci MA: Zinc-finger
transcription factor slug contributes to the survival advantage of
chronic myeloid leukemia cells. Cell Signal. 22:1247–1253. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Vitali R, Mancini C, Cesi V, Tanno B,
Mancuso M, Bossi G, Zhang Y, Martinez RV, Calabretta B, Dominici C
and Raschellà G: Slug (SNAI2) Down-Regulation by RNA interference
facilitates apoptosis and inhibits invasive growth in neuroblastoma
preclinical models. Clin Cancer Res. 14:4622–4630. 2008. View Article : Google Scholar : PubMed/NCBI
|
